Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib

Francis, Jose; Dubashi, Biswajit; Sundaram, Rajan; Pradhan, S.C.; Chandrasekaran, Adithan

doi:10.1007/s12032-015-0665-0

Cited by 19 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, there was as high as 95.5% of patients in high-risk group (Sokal scoring system) and 68.2% of patients in high-risk group (Hasford scoring system) in CML-T group, and these patients all received imatinib therapy after definite diagnosis, according to the criterion of Chinese guidelines for CML 16. At present, it was reported that the Sokal and Hasford scoring systems were significantly associated with the overall survival of CML-chronic phase patients treated with imatinib ( P =0.014 and 0.016, respectively) 17. Yahng et al18 also reported that all three high-risk groups (Sokal, Hasford and EUTOS) showed significantly lower incidence of both Complete Cytogenetic Response (CCyR) and MMR compared to low-risk groups; therefore, we considered that the poor EFS of patients in CML-T group may be involved with a higher proportion of patients with high risk in Sokal and Hasford scoring systems.…”

Section: Discussionmentioning

confidence: 93%

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Liu

Fan

et al. 2017

OTT

View full text Add to dashboard Cite

The aim of this study was to investigate the clinical characteristics and efficacy of chronic myeloid leukemia (CML) onset with extreme thrombocytosis. A total of 121 newly diagnosed and untreated CML patients in chronic phase with complete clinical information from the First Hospital of Jilin University, from January 2010 to December 2014 were retrospectively recruited. Based on the platelet (PLT) count, 22 patients were assigned into CML with thrombocytosis (CML-T) group (PLT >1,000×109/L) and 65 patients were classified into CML without extreme thrombocytosis (CML-N) group (PLT ≤1,000×109/L). Fifty-four point five percent of patients in the CML-T group were female, which was higher than that in the CML-N group (27.7%) (P=0.022). Except for gender, there was no significant difference for clinical information of patients between the two groups. For Sokal and Hasford scoring systems, the percentage of patients at high risk in the CML-T group were higher than those in the CML-N group, 95.5% vs 52.3% (P=0.000) and 68.2% vs 41.5% (P=0.031), respectively; however, there was no significant difference for European Treatment and Outcome Study (EUTOS) score system between the two groups (P=0.213). In terms of major molecular response (MMR) rate, the percent of patients with MMR in CML-T group was lower than that in CML-N group at 36 months after tyrosine kinase inhibitor therapy (P=0.037). Up until December 2016, the median of event-free survival was 21 months in the CML-T group, however, that was not reached in the CML-N group (P=0.027). The majority of CML patients with extreme thrombocytosis were females, and compared to patients in the CML-N group, the percentage of high risk patients based on the Sokal and Hasford scoring systems was higher in the CML-T group, and the median event-free survival of patients was shorter.

show abstract

Section: Discussionmentioning

confidence: 93%

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Liu

Fan

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…11 The above scores were widely implemented to evaluate treatment response and long-term outcome of CML patients receiving defined treatment. 6,[12][13][14][15] However, there lacked the risk prediction in disease-specific mortality. In 2016, the EUTOS long-term survival (ELTS) score was proposed in a clinical study enrolling a cohort of 2290 imatinib-treated patients with chronic-phase CML (CML-CP) diagnosed between 2002 and 2006 and showed a better ability to determine the probability of dying from CML.…”

Section: Introductionmentioning

confidence: 99%

<p>Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study</p>

Yang¹,

Bai²,

Shi³

et al. 2020

CMAR

View full text Add to dashboard Cite

These authors contributed equally to this workPurpose: To validate the clinical efficacy of the recently developed EUTOS long-term survival (ELTS) score in a real-world setting. Patients and Methods: A total of 479 chronic myeloid leukemia (CML) patients treated with frontline imatinib between January 2010 and December 2017 were enrolled in this retrospective study. The ELTS score was evaluated on the end-points including complete cytogenetic response (CCyR), progression-free survival (PFS), overall survival (OS) and CML-related death, and the efficiency of the ELTS score was further compared with the historical Sokal, Hasford, EUTOS scores. Results: With a median follow-up of 69 months (range, 9-112 months), 462 evaluable patients were stratified into the ELTS low-risk (n = 230), ELTS intermediate-risk (n = 168) and ELTS high-risk (n = 64) groups. For the regular assessment indicators like CCyR, PFS and OS, the ELTS scoring system could effectively identify the corresponding risk groups, similarly with the results provided by previous scoring systems. With respect to the CML-related death, the ELTS score could accurately identify a highrisk group with a significantly higher risk of dying of CML, and the 5-year cumulative incidence occurred in the ELTS high-, intermediate-, and low-risk groups was 11% (95% CI: 3-19%), 5% (95% CI: 1-9%) and 2% (95% CI: 0-4%), respectively. Most notably, the ELTS score outperformed the Sokal, Hasford and EUTOS scores without statistical difference among different risk groups. Conclusion: The ELTS score could effectively predict the prognosis of imatinib-treated CML patients in real-life settings.

show abstract

“…As more becomes known regarding how genetics affects responses to dasatinib, pharmacogenomics may be used in the future to prescribe individualized doses. For example, variations in the P‐glycoprotein allele ATP binding cassette subfamily B member 1 ( ABCB1 ) affected the transport of dasatinib, imatinib, and nilotinib into cells, and thus have implications for efficacy at a given dose . Another study examined the influence of genetic polymorphisms in ABCB1 and ATP binding cassette subfamily G member 2 ( ABCG2 ) (which help to confer multidrug resistance), the transcription factor Oct1, risk scores (Sokal, European Treatment and Outcome Study [EUTOS], and Hasford), and trough concentrations of imatinib on CCyR .…”

Section: Discussionmentioning

confidence: 99%

“…55 Another study examined the influence of genetic polymorphisms in ABCB1 and ATP binding cassette subfamily G member 2 (ABCG2) (which help to confer multidrug resistance), the transcription factor Oct1, risk scores (Sokal, European Treatment and Outcome Study [EUTOS], and Hasford), and trough concentrations of imatinib on CCyR. 56 The investigators found that a specific variant in ABCG2 correlated with increased CCyR and thus increased survival. 56 Answers to these questions and others will come from prospective clinical trials.…”

Section: Discussionmentioning

confidence: 99%

“…56 The investigators found that a specific variant in ABCG2 correlated with increased CCyR and thus increased survival. 56 Answers to these questions and others will come from prospective clinical trials. Many ongoing trials, as detailed above, are designed to determine how to modify the dose of dasatinib, the optimal time to modify dosing, the patients best suited for dose modifications, and the level of response that should be maintained on a modified dose.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dasatinib dose management for the treatment of chronic myeloid leukemia

Talpaz

Saglio

Atallah

et al. 2018

Cancer

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) has evolved into a chronic disease that is managed with tyrosine kinase inhibitor therapy. Now that long‐term survival has been achieved in patients with CML, the focus of treatment has shifted to dose optimization, with the goal of maintaining response while improving quality of life. In this review, the authors discuss optimizing the dose of the second‐generation tyrosine kinase inhibitor dasatinib. Once‐daily dosing regimens for dasatinib in the first and later lines of treatment were established through long‐term (5‐year and 7‐year) trials. Recently published data have indicated that further dose optimization may maintain efficacy while minimizing adverse events. Results obtained from dose optimization and discontinuation trials currently in progress will help practitioners determine the best dose and duration of dasatinib for patients with CML, because treatment decisions will be made through continued discussions between physicians and patients. Cancer 2018;124:1660‐72. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib

Cited by 19 publications

References 25 publications

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

<p>Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study</p>

Dasatinib dose management for the treatment of chronic myeloid leukemia

Contact Info

Product

Resources

About